SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Emisphere
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
272 19 0 EMIS
Emcee:  L. Remmel Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
197One or two of those trials are already completed. Potential partner(s) may ask fMiljenko Zuanic-11/25/2002
196Thanks. Do you have any idea what it will cost to run these trials? Can they fuMadharry-11/24/2002
195<<The "obviously" is not obvious to me. >> But, it is to Miljenko Zuanic-11/24/2002
194The "obviously" is not obvious to me. What do you think the questions Madharry-11/23/2002
193First was liquid formulation because they didn't have technology solid one. Miljenko Zuanic-11/22/2002
192Perhaps this is a stupid question but was there an advantage to having liquid hMadharry-11/22/2002
191If anyone have relevant info (or can point where to search: patents, literature,Miljenko Zuanic-11/20/2002
190Nothing new. But, this sentence may be problematic: <<One study entitled Miljenko Zuanic-11/12/2002
189<<Actually, it was big mistake to do PIII in first place>> Science whmpa-11/8/2002
188Tuck, <<So clinically relevant, but not quite as good as LMWH, and compliMiljenko Zuanic-11/7/2002
187From ASH: >>[558] Oral SNAC-Heparin vs. Enoxaparin for Preventing Venous tuck-11/7/2002
186Oral heparin and oral insulin very alive, according to management. Seeking partnMiljenko Zuanic-11/6/2002
185>>WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, Inc., one otuck-9/24/2002
184EMIS oral delivery technology dos work, imo. Management, so far, failed. [eom]Miljenko Zuanic-8/7/2002
183Continuation (financial data) EMISPHERE TECHNOLOGIES, INC. EMISPHERE TECHNOLOGIEhmpa-8/6/2002
182Conference call on Q2 available till 8/12, and worth listening: biz.yahoo.com Inhmpa-8/6/2002
181Tuck, I am aware of the Nobex effort and GSK collaboration. Waiting for postersMiljenko Zuanic-6/20/2002
180Miljenko, I used to think EMIS had no competitors in the area of orally delivertuck-6/20/2002
179Detailed account of the Abbas et.al presentation: biz.yahoo.com Researcher Fromhmpa-6/16/2002
178A Novel Per-Oral Insulin Formulation for Human Subjects Abstract Number: 5Miljenko Zuanic-6/16/2002
177Status of oral insulin: media.corporate-ir.net Oral Insulin Product Class: Prohmpa-6/8/2002
176First Clamp study is completed (capsule, data still unknown) in healthy human TIMiljenko Zuanic-5/22/2002
175Very disappointing emis compound was not first to partner. Maybe the clamp studkeokalani'nui-5/22/2002
174Message 17499534 And what are you guys waiting for? Next Spring?Miljenko Zuanic-5/22/2002
173Had they asked the trial participants to taste the liquid oral heparin before aghmpa-5/16/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News